Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FIB991
- Development stage
- Preclinical
- Lead developer
- Fibrocor Therapeutics
- Modality
- Small Molecules
01
Overview
FIB991 is a small molecule drug candidate developed by Fibrocor Therapeutics. It acts as a modulator of the YAP/TAZ pathway, which is a crucial mechanotransduction pathway involved in fibrotic processes. By inhibiting the YAP/TAZ pathway, FIB991 aims to prevent the activation of fibroblasts and halt the progression of fibrosis. Preclinical studies have demonstrated its potent anti-fibrotic activities in both lung and kidney models. The drug is currently in lead optimization, with the selection of a pre-clinical candidate imminent, and clinical trials are planned to commence in 2025 for chronic allograft nephropathy.
02
Targets
SIK1 (Salt-inducible kinase 1)
Beyond the preview
Go deeper on FIB991.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FIB991.